Flerie invests in venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges.
Location: Sweden, Stockholm
Employees: 1-10
Founded date: 2011
Investment Type: Venture Capital
Portfolio 32
| Date | Name | Website | Total Raised | Location |
| 09.02.2023 | Prokarium | prokarium.com | $35.62M | United Kin... |
| 11.10.2022 | Alder Ther... | aldertx.com | - | Sweden, So... |
| 08.09.2022 | AnaCardio | anacardio.com | $41.56M | Sweden |
| 08.09.2022 | NorthX Bio... | nxbio.com | - | Sweden, Tu... |
| 20.08.2022 | Vitara Bio... | vitara.com | $50M | United Sta... |
| 20.08.2022 | Xintela AB | xintela.se | $939.79K | Sweden, Lu... |
| 08.05.2022 | A3P Biomed... | a3p.com | - | - |
| 25.04.2022 | Bohus BioT... | bohusbiotech.com | - | - |
| 06.04.2022 | XNK Therap... | xnktherapeutics.com | - | Sweden, Hu... |
| 06.04.2022 | Geneos The... | geneostx.com | $10M | United Sta... |
Show more
Mentions in press and media 20
| Date | Title | Description |
| 28.08.2026 | Biosergen's Rights Issue Oversubscribed | Biosergen's Rights Issue Oversubscribed Fri, Aug 28, 2026 15:00 CET Report this content Biosergen AB (publ) ("Biosergen" or the "Company") today announces the outcome of the rights issue of shares (the "Rights Issue... |
| 19.08.2026 | Biosergen publishes interim report for the first half year 2026 | Biosergen publishes interim report for the first half year 2026 Wed, Aug 19, 2026 09:00 CET Report this content Biosergen Secures Funding Through Planned Merger Together with Flerie August 19, 2026: Biosergen AB (“Biosergen” or the “Company... |
| 06.08.2026 | Bulletin from the extraordinary general meeting of Biosergen AB (publ) | Bulletin from the extraordinary general meeting of Biosergen AB (publ) Thu, Aug 06, 2026 16:36 CET Report this content Biosergen AB, reg. no. 559304-1295 ("Biosergen" or the "Company"), held its extraordinary general mee... |
| 16.07.2026 | Flerie publishes merger document | Flerie publishes merger document Thu, Jul 16, 2026 18:00 CET Report this content On 26 June 2026, Biosergen AB (“Biosergen”) announced that the Boards of Directors of Flerie AB (publ) (“Flerie”) and Biosergen jointly have adopted a merger p... |
| 08.07.2026 | Notice of extraordinary general meeting in Biosergen AB | Notice of extraordinary general meeting in Biosergen AB Wed, Jul 08, 2026 11:00 CET Report this content The shareholders of Biosergen AB, Reg. No. 559304-1295 (the "Company" or “Biosergen”), are invited to attend the extraordinary... |
| 26.06.2026 | Statement from the Board of Directors of Biosergen regarding the merger with Flerie | Statement from the Board of Directors of Biosergen regarding the merger with Flerie Fri, Jun 26, 2026 17:45 CET Report this content This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen... |
| 26.06.2026 | The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie | The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie Fri, Jun 26, 2026 17:40 CET Report this content NOT FOR RELEASE, PUBLICATION OR DISTRIBUT... |
| 26.06.2026 | Flerie and Biosergen have agreed on a merger plan – Flerie’s first new investment since its listing on Nasdaq Stockholm | Flerie and Biosergen have agreed on a merger plan – Flerie’s first new investment since its listing on Nasdaq Stockholm Fri, Jun 26, 2026 17:35 CET Report this content THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIREC... |
| 11.01.2025 | AnaCardio's €19 Million Leap: A New Dawn for Heart Failure Treatment | In the world of biopharmaceuticals, every funding round can feel like a heartbeat—vital and pulsating with potential. AnaCardio, a clinical-stage startup based in Stockholm, has just secured €19 million (approximately USD 19 million) to adv... |
| 10.01.2025 | AnaCardio pumps €19 million into heart failure treatment innovation | AnaCardio, a clinical-stage biopharmaceutical startup headquartered in Stockholm, has secured €17.8 million in a Series A extension round to develop their drug candidate AC01. The financing was co-led by Novo Holdings, Pureos Bioventures, a... |
Show more